Technology | FFR Technologies | March 06, 2019

FDA Clears Abbott's New FFR Coronary Lesion Assessment Technology

The technology assesses the heart at rest while avoiding vasodilators

Abbott's Resting Full-cycle Ratio (RFR) intravascular diagnostic test is a newer type of fractional flow reserve (FFR) physiologic assessment. RFR is used to help identify significant narrowings of coronary arteries to determine the need for a stent or if a patient can be treated medically. Abbott FFR.

Abbott's Resting Full-cycle Ratio (RFR) intravascular diagnostic test is a newer type of fractional flow reserve (FFR) physiologic assessment. RFR is used to help identify significant narrowings of coronary arteries to determine the need for a stent or if a patient can be treated medically. 

March 5, 2019 –  The U.S. Food and Drug Administration (FDA) cleared Abbott's Resting Full-cycle Ratio (RFR) intravascular diagnostic test to identify significant narrowing of coronary arteries to determine the need for a stent or if a patient can be treated medically. 

The standard technology to assess severity of coronary lesions is fractional flow reserve (FFR), which requires the injection of vasodilator drugs to induce pharmacologic stress. Physicians can use the RFR diagnostic test to detect the severity of coronary artery stenosis at rest, without administering potentially costly stressor agents like adenosine, which causes patient discomfort and to lengthens procedure time.

“Accuracy in identifying the severity of arterial narrowing or blockages is critical in guiding if and when a stent should be implanted, avoiding unnecessary procedures,” said Ziad A. Ali, M.D., director of intravascular imaging and physiology at Columbia University Medical Center's Center for Interventional Vascular Therapy. “Abbott’s RFR provides interventionalists with a new, effective method of analysis that identifies important stenoses with the least discomfort, offering a better experience for patients.”

Late-breaking trial results from the RE-VALIDATE study, an all-comers prospective analysis of retrospective real-world hospital data, were presented yesterday at the Cardiovascular Research Technologies (CRT) 2019 conference in Washington, D.C. During the study, RFR demonstrated equivalence against instantaneous wave-free ratio (iFR), an older version of resting coronary artery stenosis severity assessment, with overall diagnostic accuracy of 97.8 percent.[1]

The RFR technology also offers capabilities to determine the most significant blockage in arteries with multiple lesions and offers improved security with full encryption of patient data. Additionally, it will be used with the new wireless PressureWire X, which is uniquely designed for confident and accurate physiology measurements.

Find more information, including U.S. safety information.

For more information: www.abbott.com

 

References: 

1. Kumar, G, et al. Real world validation of the Resting Full-cycle Ratio (RFR): A novel non-hyperemic index of coronary artery stenosis severity. Presented at CRT 2019, Washington D.C.

2. Svanerud J, Ahn JM, Jeremias A, etal. Validation of a novel non-hyperaemic index of coronary artery stenosis severity: the Resting Full-cycle Ratio (VALIDATE RFR) study. EuroIntervention. 2018 Sep 20;14(7):806-814. doi: 10.4244/EIJ-D-18-00342.

3. Joo Myung Lee, Ki Hong Choi, Jonghanne Park, et al. Physiological and Clinical Assessment of Resting Physiological Indexes. https://doi.org/10.1161/CIRCULATIONAHA.118.037021Circulation. 2018;139:889–900.

 

 

 

Related Content

An example of the Medis QCA angiography imaging derived fractional flow reserve (FFR) assessment. This technology removes the need for pressure wires and adenosine used in traditional FFR assessments of the coronary arteries.

An example of the Medis QCA angiography imaging derived fractional flow reserve (FFR) assessment. This technology removes the need for pressure wires and adenosine used in traditional FFR assessments of the coronary arteries.

News | Cath Lab | July 22, 2021
July 22, 2021 — Medis Medical Imaging is partnering with CORRIB Core Lab and Sinomed in randomized clinical trial of
ast End Medical announced it received U.S. Food and Drug Administration (FDA) clearance for the company's SafeCross Transseptal Radiofrequency (RF) Puncture and Steerable Balloon Introducer System. The 3-in-1 system, which includes a steerable introducer sheath with an ultra-visible positioning balloon and radiofrequency (RF) puncture dilator, aims to provide a predictable and safe solution for electrophysiology (EP) and structural heart interventions requiring left atrial access.
News | Cath Lab | July 14, 2021
July 13, 2021 — East End Medical announced it received U.S.
There is a trend in interventional cardiology that is now being called “renalism,” where patients with poor renal function are being excluded from interventional procedures because they are automatically considered too high risk. However, some hospitals are also creating cardio-renal care teams so these patients can be cared for by a team of experts rather than interventional cardiologists going it alone. #SCAI21 #SCAI2021 Creating a card0-renal program.

There is a trend in interventional cardiology that is now being called “renalism,” where patients with poor renal function are being excluded from interventional procedures because they are automatically considered too high risk. However, some hospitals are also creating cardio-renal care teams so these patients can be cared for by a team of experts rather than interventional cardiologists going it alone.

Feature | Cath Lab | May 14, 2021 | By Dave Fornell, Editor
There is a trend in interventional cardiology that is now being called “renalism,” where patients with poor renal fun
Abbott recently announced its new interventional imaging platform powered by Ultreon 1.0 Software, has gained European CE marked. This first-of-its-kind imaging software merges optical coherence tomography (OCT) intravascular imaging with the power of artificial intelligence (AI) for enhanced visualization. The new Ultreon Software can automatically detect the severity of calcium-based blockages and measure vessel diameter to enhance the precision of physicians’ decision-making during coronary stenting proc

Abbott recently announced its new interventional imaging platform powered by Ultreon 1.0 Software, has gained European CE marked. This first-of-its-kind imaging software merges optical coherence tomography (OCT) intravascular imaging with the power of artificial intelligence (AI) for enhanced visualization. The new Ultreon Software can automatically detect the severity of calcium-based blockages and measure vessel diameter to enhance the precision of physicians’ decision-making during coronary stenting procedures.

News | Cath Lab | May 12, 2021
May 12, 2021 — Abbott recently announced its new interventional imaging platform powered by Ultreon 1.0 Software, has
SCAI 2021 late-breaking presentations included the data on the Medtronic Harmony transcatheter pulmonary valve, cutting radial access hemostasis time by 50 percent, improving cardiogenic shock survival to 71 percent, and data showing very high mortality in COVID patients who suffer a STEMI heart attack. #SCAI21 #SCAI2021

SCAI 2021 late-breaking presentations included the data on the Medtronic Harmony transcatheter pulmonary valve, cutting radial access hemostasis time by 50 percent, improving cardiogenic shock survival to 71 percent, and data showing very high mortality in COVID patients who suffer a STEMI.

Feature | Cath Lab | May 06, 2021 | By Dave Fornell, Editor
April 29, 2021 — Here is the list of late-breaking study presentations and links to articles about each of them from
Most Stable Ischemic Heart Disease Patients Did Not Meet ISCHEMIA Trial Enrollment Criteria, raising questions about its application in real-world practice. #SCAI2021 Getty Images

Getty Images

News | Cath Lab | May 03, 2021
May 3, 2021 – Results from a new study find a broad range of patients who typically undergo revascularization for sta
New study demonstrates depression, HIV, mental health, obesity, alcohol and drug abuse are risk factors on most common type of heart disease in young black patients. Photo by Dave Fornell
News | Cath Lab | April 29, 2021
April 29, 2021 – A retrospective analysis of risk factors for coronary artery disease (CAD) in young African American
There are far fewer patients coming to hospitals with heart attacks during the COVID-19 pandemic as compared to averages prior to the pandemic. This has raised concerns that delayed treatment will cause an uptick in cardiac deaths and heart failure. Photo from Getty Images 

There are far fewer patients coming to hospitals with heart attacks during the COVID-19 pandemic as compared to averages prior to the pandemic. This has raised concerns that delayed treatment will cause an uptick in cardiac deaths and heart failure. Photo from Getty Images 

News | Cath Lab | April 28, 2021
April 28, 2021 – Results from a retrospective observational study, presented today at...
A cardiac cath lab at Henry Ford Hospital in Detroit. Photo by Dave Fornell

A cardiac cath lab complex PCI case at Henry Ford Hospital in Detroit. Photo by Dave Fornell

News | Cath Lab | April 28, 2021